Pancreatic beta‐cell function dynamics in youth with GCK, HNF1A, and KCNJ11 genes mutations during mixed meal tolerance test

• Published in: Pediatric diabetes Vol. 23; no. 7; pp. 1009 - 1016
• Main Authors: Stankute, Ingrida, Dobrovolskiene, Rimante, Danyte, Evalda, Steponaviciute, Rasa, Schwitzgebel, Valerie M., Verkauskiene, Rasa
• Format: Journal Article
• Language: English
• Published: Former Munksgaard John Wiley & Sons A/S 01.11.2022; Wiley Subscription Services, Inc
• Subjects: Adolescent; beta‐cell function; Blood Glucose; C-Peptide; Diabetes; Diabetes mellitus; Diabetes Mellitus, Type 2 - genetics; Glycated Hemoglobin; Hepatocyte Nuclear Factor 1-alpha - genetics; Humans; mixed meal tolerance test; monogenic diabetes; Monogenic Diabetes and Other Genetic Disorders of Glucose Metabolism; Mutation; Patients; targeted treatment; beta-cell function; monogenic diabetes; C-peptide; mixed meal tolerance test; targeted treatment
• ISSN: 1399-543X; 1399-5448
• DOI: 10.1111/pedi.13404

Objective The aims were (1) to assess beta‐cell function in GCK diabetes patients over 2‐year period; (2) to evaluate the dynamics of beta‐cell function in HNF1A and KCNJ11 patients after treatment optimization; using mixed meal tolerance test (MMTT) as a gold standard for non‐invasive beta‐cell function assessment. Research Design and Methods Twenty‐two GCK diabetes patients, 22 healthy subjects, 4 patients with HNF1A and 2 with KCNJ11 were recruited. Firstly, beta‐cell function was compared between GCK patients versus controls; the dynamics of beta‐cell function were assessed in GCK patients with two MMTTs in 2‐year period. Secondly, the change of beta‐cell function was evaluated in HNF1A and KCNJ11 patients after successful treatment optimization in 2‐year period. Results GCK diabetes patients had lower area under the curve (AUC) of C‐peptide (CP), average CP and peak CP compared to controls. Also, higher levels of fasting, average, peak and AUC of glycemia during MMTT were found in GCK patients compared to healthy controls. No significant changes in either CP or glycemia dynamics were observed in GCK diabetes group comparing 1st and 2nd MMTTs. Patients with HNF1A and KCNJ11 diabetes had significantly improved diabetes control 2 years after the treatment was optimized (HbA1c 7.1% vs. 5.9% [54 mmol/mol vs. 41 mmol/mol], respectively, p = 0.028). Higher peak CP and lower HbA1c were found during 2nd MMTT in patients with targeted treatment compared to the 1st MMTT before the treatment change. Conclusion In short‐term perspective, GCK diabetes group revealed no deterioration of beta‐cell function. Individualized treatment in monogenic diabetes showed improved beta‐cell function.